RESUMO
Trastuzumab emtansine and trastuzumab deruxtecan are widely used in breast cancer and other solid tumor malignancies. Thrombocytopenia is a common adverse event associated with the use of these agents that can lead to a treatment delay, reduction in dose intensity, and discontinuation. The role of thrombopoietin receptor agonists (TPO-RA) remains unknown in this setting. We report a case series of 6 individuals with breast cancer that experienced dose-reductions and therapy delays due to thrombocytopenia secondary to trastuzumab emtansine or trastuzumab deruxtecan therapy and received intervention with TPO-RA. All 6 were able to resume therapy with TPO-RA support.
Assuntos
Anemia , Neoplasias da Mama , Imunoconjugados , Trombocitopenia , Humanos , Feminino , Ado-Trastuzumab Emtansina/uso terapêutico , Receptores de Trombopoetina/uso terapêutico , Receptor ErbB-2/genética , Receptor ErbB-2/uso terapêutico , Anticorpos Monoclonais Humanizados/uso terapêutico , Trastuzumab/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Trombocitopenia/induzido quimicamente , Trombocitopenia/tratamento farmacológico , Anemia/induzido quimicamente , Imunoconjugados/uso terapêuticoRESUMO
Atypical chronic lymphocytic lymphoma (CLL) with CCND1 translocation is poorly described, particularly in the era of modern inhibitors of the B-cell receptor pathway. We present a patient with atypical CLL who had a significant response to ibrutinib, highlighting the effectiveness of this agent in higher risk CLL subgroups.